



## Clinical trial results:

### A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy,

### Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated

### Interferon Alpha-2a, Nucleos(t)ide Analog With or Without JNJ-56136379 in Treatment-naïve

### Patients With HBeAg Positive Chronic Hepatitis B Virus Infection

## Summary

EudraCT number	2019-004978-26
Trial protocol	GB FR DE
Global end of trial date	12 February 2024

## Results information

Result version number	v1 (current)
This version publication date	17 April 2025
First version publication date	17 April 2025

## Trial information

### Trial identification

Sponsor protocol code	73763989PAHPB2005
-----------------------	-------------------

### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04439539
WHO universal trial number (UTN)	-

Notes:

## Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route 202, Raritan, United States, 08869
Public contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

## Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 February 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 February 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of the study was to assess the efficacy of a treatment regimen of JNJ-73763989 (JNJ-3989) plus pegylated interferon alpha-2a (PegIFN-alpha-2a) plus nucleos(t)ide analog (NA: tenofovir disoproxil [TDF]/tenofovir alafenamide [TAF]).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 October 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Japan: 4
Country: Number of subjects enrolled	Russian Federation: 10
Country: Number of subjects enrolled	Türkiye: 9
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	United States: 1
Worldwide total number of subjects	54
EEA total number of subjects	16

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	54
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The Study consisted of 3 phases: induction phase (IP), consolidation phase (CP) and follow-up (FU) phase. Response-guided treatment (RGT): hepatitis B (HB) surface antigen (HBsAg) less than(<) 10 international unit per millilitre (IU/mL) and RGT was removed post protocol amendment 5 (PA 5).

### Pre-assignment

Screening details:

Nucleos(t)ide (NA) treatment completion criteria: HBsAg <10 IU/mL, HB envelop antigen (HBeAg)-negative, HB virus deoxyribonucleic acid (HBV DNA) <lower limit of quantification (LLOQ) and alanine aminotransferase (ALT) <3\*upper limit of normal (ULN).

### Period 1

Period 1 title	IP:Day 1-Week 36(post-PA5)/52(prior-PA5)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a

Arm description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegIFN-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegIFN-alpha-2a, started pegIFN-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

Arm type	Experimental
Investigational medicinal product name	JNJ-73763989
Investigational medicinal product code	JNJ-73763989
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W for  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAF 25 mg tablet orally QD for up to  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAD 245 mg tablet orally

QD for up to  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

Investigational medicinal product name	JNJ-56136379
Investigational medicinal product code	JNJ-56136379
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received JNJ-6379 250 mg tablet

orally QD for  $\geq 36$ -weeks (post PA 5) to  $\leq 52$ -weeks (prior to PA 5)

<b>Arm title</b>	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
------------------	---

Arm description:

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg

SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks.

After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Arm type	Experimental
Investigational medicinal product name	JNJ-73763989
Investigational medicinal product code	JNJ-73763989
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received JNJ-3989 200 mg SC

injection Q4W for 36 weeks.

Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAF 25 mg tablet orally

QD for 36 weeks.

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAD 245 mg tablet orally

QD for 36 weeks.

<b>Arm title</b>	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
------------------	---

Arm description:

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Arm type	Experimental
Investigational medicinal product name	JNJ-73763989
Investigational medicinal product code	JNJ-73763989
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W for 36 weeks.

Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAF 25 mg tablet orally QD for 36 weeks.

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAD 245 mg tablet orally QD for 36 weeks.

<b>Number of subjects in period 1</b>	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Started	27	8	19
Completed	26	8	17
Not completed	1	0	2
Consent withdrawn by subject	1	-	2

**Period 2**

Period 2 title	CP Phase: CP Week 1 to 12
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a

## Arm description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

Arm type	Experimental
Investigational medicinal product name	JNJ-73763989
Investigational medicinal product code	JNJ-73763989
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

## Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

Investigational medicinal product name	JNJ-56136379
Investigational medicinal product code	JNJ-56136379
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Participants received JNJ-6379 250 mg tablet orally QD from CP Week 1 to 12.

Investigational medicinal product name	pegylated interferon alpha-2a
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

## Dosage and administration details:

Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

## Dosage and administration details:

Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants received TAD 245 mg tablet orally  
QD from CP Week 1 to 12.

<b>Arm title</b>	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
------------------	---

**Arm description:**

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Arm type	Experimental
Investigational medicinal product name	JNJ-73763989
Investigational medicinal product code	JNJ-73763989
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants received JNJ-3989 200 mg SC  
injection Q4W from CP Week 1 to 12.

Investigational medicinal product name	pegylated interferon alpha-2a
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally  
QD from CP Week 1 to 12.

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants received TAD 245 mg tablet orally  
QD from CP Week 1 to 12.

<b>Arm title</b>	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
------------------	---

Arm description:

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Arm type	Experimental
Investigational medicinal product name	JNJ-73763989
Investigational medicinal product code	JNJ-73763989
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received JNJ-3989 200 mg SC injection Q4W from CP Week 1 to 12.

Investigational medicinal product name	pegylated interferon alpha-2a
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received PegIFN-alpha-2a 180 mcg SC injection QW from IP Week 36 for 12 weeks. Those who passed IP W36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a from their next visit up to CP Week 12.

Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAF 25 mg tablet orally QD from CP Week 1 to 12.

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received TAD 245 mg tablet orally QD from CP Week 1 to 12.

Number of subjects in period 2	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Started	26	8	17
Subjects actually started CP	25 <sup>[1]</sup>	7 <sup>[2]</sup>	17

Completed	26	8	17
-----------	----	---	----

#### Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: One participant discontinued JNJ-3989 treatment due to treatment failure/relapse and moved directly from IP to FU phase without CP.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: One participant discontinued JNJ-3989 treatment due to treatment failure/relapse and moved directly from IP to FU phase without CP.

### Period 3

Period 3 title	FU Phase: FU Week 1 to 48
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a

#### Arm description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

Arm type	Experimental
Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

#### Dosage and administration details:

Participants received TAF 25 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

#### Dosage and administration details:

Participants received TDF 245 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

<b>Arm title</b>	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
------------------	---

**Arm description:**

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Arm type	Experimental
Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants received TDF 245 mg tablet orally QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

<b>Arm title</b>	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
------------------	---

**Arm description:**

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Arm type	Experimental
Investigational medicinal product name	Tenofovir alafenamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

---

**Dosage and administration details:**

Participants received TAF 25 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

Investigational medicinal product name	Tenofovir disoproxil
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants received TDF 245 mg tablet orally

QD up to FU Week 2. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU Week 2. If NA completion criteria was not met, NA was continued till the end of FU phase (FU Week 48).

<b>Number of subjects in period 3</b>	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Started	26	8	17
Completed	26	6	17
Not completed	0	2	0
Consent withdrawn by subject	-	1	-
Unspecified	-	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
-----------------------	---

#### Reporting group description:

Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$  to  $\leq 52$  weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

Reporting group title	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
-----------------------	---

#### Reporting group description:

Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Reporting group title	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
-----------------------	---

#### Reporting group description:

In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.

Reporting group values	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Number of subjects	27	8	19
Age Categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	35.6 ± 9.95	27.3 ± 9.95	33.6 ± 11.15
Gender categorical Units: Subjects			
Male	12	5	11
Female	15	3	8

<b>Reporting group values</b>	Total		
Number of subjects	54		
Age Categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Male	28		
Female	26		

## End points

### End points reporting groups

Reporting group title	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
Reporting group description: Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for $\geq 36$ to $\leq 52$ weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.	
Reporting group title	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
Reporting group description: Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.	
Reporting group title	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Reporting group description: In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.	
Reporting group title	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
Reporting group description: Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for $\geq 36$ to $\leq 52$ weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.	
Reporting group title	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
Reporting group description: Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment withJNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU	

phase.	
Reporting group title	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Reporting group description:	
<p>In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.</p>	
Reporting group title	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
Reporting group description:	
<p>Prior to PA 5, in IP, enrolled participants received JNJ-3989 200 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD for &gt;=36 to &lt;=52 weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit. Per PA 6, JNJ-6379 treatment was stopped. Post CP Week 12, participants entered 48-week FU phase and stopped JNJ-3989+PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.</p>	
Reporting group title	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
Reporting group description:	
<p>Per PA 5, in the IP, enrolled participants received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegINF-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.</p>	
Reporting group title	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Reporting group description:	
<p>In the IP, participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection Q4W plus NA (TDF 245 mg/TAF 25 mg) tablet orally QD for 36 weeks. After completion of IP Week 36, participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if completion criteria was not met, NA was continued till the end of FU phase.</p>	
Subject analysis set title	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol
Subject analysis set description:	
<p>Prior PA 5, participants received JNJ-3989 200 mg SC injection 4th weekly(Q4W) + JNJ-6379 250 mg tablets orally once daily (QD) + NA (TDF 245 mg/TAF 25 mg) tablet orally QD in IP for &gt;=36 to &lt;=60 weeks. Participants who met RGT criterion or reached 60 weeks were considered completed IP &amp; entered 12 week CP &amp; randomized to JNJ-3989 200 mg SC injection Q4W + JNJ-6379 250 mg tablets orally QD + NA (TDF 245 mg/TAF 25 mg) tablet orally QD or JNJ-3989 200 mg SC injection Q4W + JNJ-6379 250 mg tablets orally QD + NA (TDF 245 mg/TAF 25 mg) tablets orally QD + PegIFN-alpha-2a 180 mcg SC injection QW. Post PA 5, participants not reached IP Week (W)36, started PegINF-alpha-2a at W36 for 12 weeks &amp; who passed IP W36 &amp;/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at next visit. Per PA 6 JNJ-6379 treatment discontinued. Post 12 week CP, participants entered 48 week FU phase till FU Week 48 &amp; stopped JNJ-3989 + PegIFN-alpha-2a.</p>	
Subject analysis set title	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

Per PA 5, participants in IP received JNJ-3989 200 mg SC injection for Q4W plus NA (tenofovir disoproxil 245 mg/tenofovir alafenamide 25 mg) tablets orally QD for 36 weeks. After completion of IP W36, all participants entered 12-week CP during which PegIFN-alpha-2a 180 mcg SC injection QW was added to their treatment regimen for 12-weeks. After completion of 12-week CP, all participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP W12 NA was stopped at FU W2, if completion criteria was not met NA was continued till the end of FU phase.

Subject analysis set title	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

Participants enrolled as per PA 6 received JNJ-3989 200 mg SC injection for Q4W plus NA (tenofovir disoproxil 245 mg/tenofovir alafenamide 25 mg) tablet orally QD for 36 weeks in IP. After completion of IP, participants entered 12-week CP and received PegIFN-alpha-2a 180 mcg QW for 12-week. After completion of 12-week CP, all participants entered the 48-week FU phase and stopped treatment with JNJ-3989 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP W12 NA was stopped at FU W2, if completion criteria was not met NA was continued till the end of FU phase

Subject analysis set title	IP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

Prior to PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD in IP for a RGT duration for >=36-weeks to <=52-weeks.

Subject analysis set title	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD in IP for 36 weeks.

Subject analysis set title	IP: Cohort 2 (Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (TAD 250 mg/TAF 25 mg) tablet orally QD in IP for 36 weeks.

Subject analysis set title	CP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

After completion of IP, participants entered in 12 week CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TAD 250 mg or TAF 25 mg) tablet orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC injection was added to their treatment regimen from IP Week 36 for 12 weeks.

Subject analysis set title	CP: Cohort 1 (Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

Subject analysis set title	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol

Subject analysis set description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

Subject analysis set title	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a
----------------------------	---

Subject analysis set type	Per protocol
Subject analysis set description:	
After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12 NA was stopped at FU W2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.	
Subject analysis set title	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol
Subject analysis set description:	
After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.	
Subject analysis set title	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
Subject analysis set type	Per protocol
Subject analysis set description:	
After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.	
Subject analysis set title	Induction phase
Subject analysis set type	Per protocol
Subject analysis set description:	
Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.	
Subject analysis set title	Consolidation phase
Subject analysis set type	Per protocol
Subject analysis set description:	
After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a.If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.	
Subject analysis set title	Induction phase
Subject analysis set type	Per protocol
Subject analysis set description:	
Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for >=36-weeks to <=52-weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.	
Subject analysis set title	Consolidation phase

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

Subject analysis set title	Induction phase
----------------------------	-----------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

Prior PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD for  $\geq 36$ -weeks to  $\leq 52$ -weeks. Participants who met RGT criterion/reached 52 weeks were considered to complete IP and entered 12-week CP and randomized to JNJ-3989 + JNJ-6379 + NA or JNJ-3989+JNJ-6379 + NA + PegIFN-alpha-2a 180 micrograms (mcg) SC injection once weekly (QW). Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD for 36 weeks. Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (either tenofovir disoproxil 250 mg or 25 mg tenofovir alafenamide) tablet orally QD for 36 weeks in IP. Post PA 5, participant not reached IP Week 36, started PegINF-alpha-2a at Week 36 for 12 weeks and who passed IP Week 36 and/or were randomized to CP without PegINF-alpha-2a, started pegINF-alpha-2a at their next visit.

Subject analysis set title	Consolidation phase
----------------------------	---------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

After completion of IP, participants entered the 12 weeks CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TDF 245 mg/TAF 25 mg) tablet orally QD plus PegIFN-alpha-2a 180 mcg SC QW. At the end of the CP, all participants entered the 48-weeks follow-up (FU) phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA plus PegIFN-alpha-2a. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase. If NA treatment completion criteria was met at CP Week 12, NA was stopped at FU phase Week 2, if not met, NA was continued till end of FU phase.

**Primary: Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping all Study Interventions at the end of Consolidation Phase (CP) and Without Restarting Nucleos(t)ide analog (NA) Treatment**

End point title	Percentage of Participants With Functional Cure: Hepatitis B Surface Antigen (HBsAg) Seroclearance at 24 Weeks After Stopping all Study Interventions at the end of Consolidation Phase (CP) and Without Restarting Nucleos(t)ide analog (NA) Treatment <sup>[1]</sup>
-----------------	--

End point description:

Percentage of participants with functional cure (defined as percentage of participants with HBsAg seroclearance at 24 weeks after stopping all study interventions at end of CP and without restarting NA treatment) were reported. Seroclearance of HBsAg was defined as a (quantitative) HBsAg level less than ( $<$ ) lower limit of quantification (LLOQ; 0.05 IU/mL). Per protocol analysis set: all randomised/enrolled participants who received at least 1 dose of CP study intervention and did not had any of the selected major protocol deviations that might affect the assessment of efficacy in terms of the primary endpoint at 24 weeks after stopping all study interventions of the CP.

End point type	Primary
----------------	---------

End point timeframe:

At follow-up (FU) phase Week 24

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No inferential statistics was done. Only descriptive statistics was performed.

End point values	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	8	17	
Units: percentage of participants				
number (not applicable)	0	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Participants with Treatment Emergent Adverse Events (TEAEs)
-----------------	---

End point description:

Number of participants with TEAEs were reported. An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. Safety analysis set (SAS) included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25 <sup>[2]</sup>
Units: participants	22	8	15	22

Notes:

[2] - 1 participant who moved directly from IP to FU was not counted in this arm.

End point values	CP: Cohort 1(Per PA 5):	CP: Cohort 2 (Per PA 6):	FU: Cohort 1: JNJ-3989+	FU: Cohort 1: JNJ-3989 + NA
------------------	-------------------------	--------------------------	-------------------------	-----------------------------

	JNJ-3989+NA+ PegIFN-alpha- 2a	JNJ-3989 + NA + PegIFN- alpha-2a	JNJ- 6379+NA+PegI FN-alpha-2a	+ PegIFN- alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7 <sup>[3]</sup>	17	26 <sup>[4]</sup>	8 <sup>[5]</sup>
Units: participants	7	13	17	5

Notes:

[3] - 1 participant who moved directly from IP to FU was not counted in this arm.

[4] - 25 participants from CP + 1 participant moved directly from IP.

[5] - 7 participants from CP + 1 participant moved directly from IP.

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: participants	11			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs)

End point title	Number of Participants with Treatment Emergent Serious Adverse Events (TESAEs)
-----------------	--

End point description:

Number of participants with TESAEs were reported. An AE was any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the study intervention. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are all AEs with an onset on or after the first administration of study treatment or any ongoing event that worsened in severity, intensity or frequency after the first administration of study treatment. Safety analysis set included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ- 6379+NA+PegI FN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN- alpha-2a	IP:Cohort 2(Per PA 6): JNJ- 3989+NA+PegI FN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ- 3989+JNJ- 6379+NA+PegI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: participants	0	0	0	0

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: participants	0	0	0	0

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: participants	1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants with Worst (Grade 3 or 4) Treatment-emergent DAIDS Toxicity Grade in Clinical Laboratory Tests

End point title	Number of Participants with Worst (Grade 3 or 4) Treatment-emergent DAIDS Toxicity Grade in Clinical Laboratory Tests
-----------------	---

End point description:

Laboratory parameters: Hematology (Hem): absolute lymphocyte count, (ALC), A neutrophil count (ANC), hemoglobin (Hb) , Neutrophils Band Form (NBF) , Neutrophils segmented (Neu Seg), WBC decreased (dcrsd); Chem: alanine aminotransferase (ALT) & serum glutamic pyruvic transaminase (SGPT), aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT), cholesterol (CLSTR) (fasting[F]), creatinine Kinase (Cr Kin), Glomerular filtration rate (GFR) from Creatinine (Cr) Adjusted for body surface area ((Ad.BSA), GFR Cystatin (Cy) C (Ad. BSA), low-density lipoprotein (LDL: fasting[F]), triglycerides (Tglrds[F]); Urinalysis: glycosuria. DAIDS toxicity grades: Grade (Gr) 1 (Mild), Gr 2 (Moderate), Gr 3 (Severe), Gr 4 (Potentially Life-Threatening). Here, number of participants with TE DAIDS toxicity Grade 3 or 4 were reported in this endpoint. SAS was analysed. n=0, and 99999 signify that data were not collected & analysed as timepoint was not applicable to respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: participants				
Hem:ALC:Low:Gr 3 :n=26,8,19,25,7,17,26,8,17	0	0	0	1
Hem: ANC: Gr 3: n=26,8,19,25,7,17,26,8,17	0	0	0	2
Hem: HB: Low: Gr 3 :n=26,8,19,25,7,17,26,8,17	0	0	0	1
Hem: NBF: Low: Gr4:n=0,0,0,3,0,0,1,0,1	99999	99999	99999	3
Hem:Neu Seg:Low:Gr3: n=26,8,19,25,7,17,26,8,17	0	0	0	2
Hem:WBC	0	0	0	3
dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17	1	0	0	1
Chem:ALT/SGPT:High:Gr3:n=26,8,19,25,7,17,26,8,17	0	0	0	0
Chem:AST/SGOT:High:Gr3:n=26,8,19,25,7,17,26,8,17	1	0	0	1
Chem:CLSTRL(F):High:Gr3:n=26,8,19,25,7,17,26,8,17	0	0	0	0
Chem:Cr	1	0	0	0
Kin:High:Gr3:n=26,8,19,25,7,17,26,8,17	0	0	0	0
Chem: Cr	1	0	0	0
Kin:High:Gr4:n=26,8,19,25,7,17,26,8,17	1	0	0	0
Che:GFR:Cr	1	0	0	1
Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17	1	0	0	0
Che:GFR:Cyc	0	0	0	0
Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17	2	0	0	1
Che:GFR:Cyc	0	0	1	1
Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,5,7,17,26,8,17	0	0	0	0
Chem:LDL(F):High:Gr3:n=26,8,19,25,7,17,26,8,17	0	0	1	1
Chem:Tglrds(F):High:Gr3:n=26,8,19,25,7,17,26,8,17	0	0	0	0
Urinalysis:Glycosuria:Gr3:n=17,7,7,13,6,6,12,8,5	0	0	0	0

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: participants				
Hem:ALC:Low:Gr 3 :n=26,8,19,25,7,17,26,8,17	0	0	0	0
Hem: ANC: Gr 3: n=26,8,19,25,7,17,26,8,17	0	0	0	0
Hem: HB: Low: Gr 3 :n=26,8,19,25,7,17,26,8,17	0	0	0	1

Hem: NBF: Low: Gr4:n=0,0,0,3,0,0,1,0,1	99999	99999	1	99999
Hem:Neu Seg:Low:Gr3: n=26,8,19,25,7,17,26,8,17	0	0	0	0
Hem:WBC	0	1	1	0
dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,	0	2	0	0
Chem:ALT/SGPT:High:Gr3:n=26,8,19,2 5,7,17,26,8,17	0	1	0	0
Chem:AST/SGOT:High:Gr3:n=26,8,19,2 5,7,17,26,8,17	0	0	1	0
Chem:CLSTRL(F):High:Gr3:n=26,8,19,2 5,7,17,26,8,17	0	2	0	0
Chem:Cr	0	0	0	0
Kin:High:Gr3:n=26,8,19,25,7,17,26,8,1	0	0	0	0
Chem: Cr	0	0	0	0
Kin:High:Gr4:n=26,8,19,25,7,17,26,8,1	0	0	0	0
Che:GFR:Cr	0	0	0	0
Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,	0	0	1	0
Che:GFR:Cyc	0	0	0	0
Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,	0	0	0	0
Che:GFR:Cyc	0	1	0	0
Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,	0	0	1	0
Chem:LDL(F):High:Gr3:n=26,8,19,25,7, 17,26,8,17	0	0	0	0
Chem:Tglrds(F):High:Gr3:n=26,8,19,25 ,7,17,26,8,17	0	0	1	0
Urinalysis:Glycosuria:Gr3:n=17,7,7,13, 6,6,12,8,5	0	0	0	1

<b>End point values</b>	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: participants				
Hem:ALC:Low:Gr 3 :n=26,8,19, 25,7,17,26,8,17	0			
Hem: ANC: Gr 3: n=26,8,19, 25,7,17,26,8,17	0			
Hem: HB: Low: Gr 3 :n=26,8,19, 25,7,17,26,8,17	0			
Hem: NBF: Low: Gr4:n=0,0,0,3,0,0,1,0,1	1			
Hem:Neu Seg:Low:Gr3: n=26,8,19,25,7,17,26,8,17	0			
Hem:WBC	0			
dcrsd:Low:Gr3:n=26,8,19,25,7,17,26,8,	0			
Chem:ALT/SGPT:High:Gr3:n=26,8,19,2 5,7,17,26,8,17	0			
Chem:AST/SGOT:High:Gr3:n=26,8,19,2 5,7,17,26,8,17	0			
Chem:CLSTRL(F):High:Gr3:n=26,8,19,2 5,7,17,26,8,17	0			
Chem:Cr	0			
Kin:High:Gr3:n=26,8,19,25,7,17,26,8,1				

Chem: Cr Kin:High:Gr4:n=26,8,19,25,7,17,26,8,1	0			
Che:GFR:Cr Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,	0			
Che:GFR:Cyc Ad.BSA:L:Gr3:n=26,8,19,25,7,17,26,8,	1			
Che:GFR:Cyc Ad.BSA:L:Gr4:n=26,8,19,25,7,17,26,8,	1			
Chem:LDL(F):High:Gr3:n=26,8,19,25,7, 17,26,8,17	0			
Chem:Tglrds(F):High:Gr3:n=26,8,19,25 ,7,17,26,8,17	0			
Urinalysis:Glycosuria:Gr3:n=17,7,7,13, 6,6,12,8,5	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Worst Treatment-emergent Abnormality in Electrocardiogram (ECGs)

End point title	Number of Participants With Worst Treatment-emergent Abnormality in Electrocardiogram (ECGs)
<p>End point description:</p> <p>Number of participants with worst treatment-emergent abnormality in ECG were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. ECG parameters included heart rate (HR; abnormally low, HR &lt;45 beats per minute (bpm) and (abnormally high HR ≥ 120 bpm; PR interval abnormally high &gt;220 milliseconds (ms); QRS interval abnormally high ≥ 120 ms; QT corrected (Fridericia QTcF) categories; borderline prolonged QTc interval &lt;450 to ≤480 ms), prolonged QTc interval &lt;480 to ≤500 ms) and pathologically prolonged QTc interval &gt;500 ms). Safety analysis set included all participants who received at least one dose of study intervention. Participants were analysed according to the study intervention they actually received.</p>	
End point type	Secondary
<p>End point timeframe:</p> <p>IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48</p>	

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: participants	0	0	0	0

End point values	CP: Cohort 1(Per PA 5):	CP: Cohort 2 (Per PA 6):	FU: Cohort 1: JNJ-3989+	FU: Cohort 1: JNJ-3989 + NA
------------------	-------------------------	--------------------------	-------------------------	-----------------------------

	JNJ-3989+NA+ PegIFN-alpha- 2a	JNJ-3989 + NA + PegIFN- alpha-2a	JNJ- 6379+NA+PegI FN-alpha-2a	+ PegIFN- alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: participants	0	0	0	0

<b>End point values</b>	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: participants	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Worst Treatment-emergent Abnormalities in Vital Signs

End point title	Number of Participants With Worst Treatment-emergent Abnormalities in Vital Signs
-----------------	---

End point description:

Number of participants with worst treatment-emergent abnormalities in vital signs were reported. Treatment-emergent abnormality was defined as the abnormalities that were worsened as compared to the abnormality at baseline; which also included the shift from abnormally high to abnormally low and vice-versa. Abnormalities in vital signs included abnormal pulse rate (PR); abnormally low,  $\leq 45$  bpm and abnormally high  $\geq 120$  bpm; diastolic blood pressure (DBP) abnormally low  $\leq 50$  mmHg, systolic blood pressure (SBP) abnormally low  $\leq 90$  mmHg. Additionally, abnormal low SBP and DBP were  $\leq 50$  mmHg and  $< +90$  mmHg. Only those categories in which at least one participant had data were reported.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

<b>End point values</b>	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ- 6379+NA+PegI FN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN- alpha-2a	IP:Cohort 2(Per PA 6): JNJ- 3989+NA+PegI FN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ- 3989+JNJ- 6379+NA+PegI
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	8	19	25
Units: participants				
DBP: High:	3	1	1	1

SBP: Low	0	1	0	1
SBP: High	2	1	3	1
Pulse rate: High	0	1	0	0

End point values	CP: Cohort 1 (Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: participants				
DBP: High:	0	1	1	1
SBP: Low	1	1	1	0
SBP: High	0	0	2	1
Pulse rate: High	0	1	0	0

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: participants				
DBP: High:	0			
SBP: Low	0			
SBP: High	1			
Pulse rate: High	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Clinically Important Abnormalities in Physical Examination

End point title	Number of Participants With Clinically Important Abnormalities in Physical Examination
-----------------	--

End point description:

Number of participants with clinically important abnormalities in physical examination were reported. Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analysed according to the study intervention they actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: participants	0	0	0	0

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: participants	0	0	0	0

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: participants	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Reached HBsAg Less Than (<) 10 (International Units Per Milliliter [IU/mL]) at the End of the Induction Phase (EOI)

End point title	Percentage of Participants Who Reached HBsAg Less Than (<) 10 (International Units Per Milliliter [IU/mL]) at the End of the Induction Phase (EOI)
-----------------	--

End point description:

Percentage of participants who reached HBsAg <10 IU/mL at the end induction phase were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this Intervention-specific appendix (ISA). Here, "n"(number analysed) signifies participants who were evaluable at specified timepoints. Data for this endpoint were planned to be collected and analysed for IP only. Here, 99999 signifies that no participant was available for the analysis.

End point type	Secondary
End point timeframe:	
At IP Week 36 and EOI; anytime up to IP Week 36 (after PA 5) or up to IP Week 52 (prior to PA 5)	

<b>End point values</b>	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	7	19	
Units: percentage of participants				
number (not applicable)				
IP Week 36 (n=13, 0, 1)	0	99999	10	
End of Induction phase (n=26, 7, 19)	15.4	37.5	10.5	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Achieve First Occurrence of HBsAg <10 IU/mL

End point title	Time to Achieve First Occurrence of HBsAg <10 IU/mL
End point description:	
Time to achieve first occurrence of HBsAg <10 IU/mL] were reported. Time to HBsAg <10 IU/mL was defined as the number of days between the date of first study treatment intake and the date of the first occurrence of HBsAg <10 IU/mL. Kaplan-Meier method was used for the estimation. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, 99999 signifies that upper limit and lower limit of CI was not estimable due to insufficient number of participants with events.	
End point type	Secondary
End point timeframe:	
From Baseline (Day 1 of IP) to Follow up Week 48	

<b>End point values</b>	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	27	8	19	
Units: weeks				
median (confidence interval 90%)	48.1 (-99999 to 99999)	84.3 (2.1 to 99999)	48.3 (36.1 to 99999)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: FU Phase: Percentage of Participants With HBsAg Seroclearance 48 Weeks After

#### Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase

End point title	FU Phase: Percentage of Participants With HBsAg Seroclearance 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase
End point description: Percentage of participants with HBsAg seroclearance 48 weeks after stopping all study interventions at the consolidation phase and without restarting NA treatment during follow up phase were reported. HBsAg seroclearance was defined as (quantitative) HBsAg < LLOQ (HBsAg 0.05 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.	
End point type	Secondary
End point timeframe: FU phase Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	6	17	
Units: percentage of participants				
number (not applicable)	11.5	16.7	11.8	

## Statistical analyses

No statistical analyses for this end point

### Secondary: FU Phase: Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <LLOQ 48 Weeks After Stopping All Study Interventions of the Consolidation Phase and Without Restarting NA Treatment During Follow up Phase

End point title	FU Phase: Percentage of Participants With Hepatitis B Virus
-----------------	---

End point description:

Percentage of participants with HBV DNA <LLOQ (<20 IU/mL) 48 weeks after stopping all study interventions of the consolidation phase and without restarting NA treatment during follow up phase were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.

End point type Secondary

End point timeframe:

FU phase: FU Week 1 up to FU Week 48

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegI FN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>	1	
Units: percentage of participants				
number (not applicable)			0	

Notes:

[6] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[7] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Percentage of Participants Who Met Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at the End of Consolidation Phase**

End point title	Percentage of Participants Who Met Nucleos(t)Ide Analog (NA) Treatment Completion Criteria at the End of Consolidation Phase
-----------------	--

End point description:

Percentage of participants meeting the protocol-defined NA treatment completion criteria at EOC were reported. NA treatment completion criteria at CP Week 12 was defined as HBsAg <10 IU/mL; HBeAg-negative; HBV DNA <20 IU/mL, that is, lower limit of quantification (LLOQ); alanine aminotransferase(ALT) <3\*ULN. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

End point type Secondary

End point timeframe:

At CP Week 12

End point values	CP: Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA+PegI	CP: Cohort 1 (Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	25	7	16	
Units: percentage of participants				
number (not applicable)	0	0	5.9	

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants with Off-treatment Virologic HBV Flares During Follow up Phase

End point title	FU Phase: Number of Participants with Off-treatment Virologic HBV Flares During Follow up Phase
End point description:	
<p>Number of participants with off-treatment virologic HBV flares were reported. Virologic flare was defined as confirmed HBV DNA &gt;peak threshold (lowest peak to qualify as virologic flare was HBV DNA &gt;200 IU/mL) in participants who were off-treatment and had HBV DNA &lt;LLOQ (&lt;20 IU/mL) at the last observed time point on all study treatments. The 3 thresholds of virologic flare was 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.</p>	
End point type	Secondary
End point timeframe:	
FU phase: FU Week 1 up to FU Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegI FN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>	1	
Units: participants			0	

Notes:

[8] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[9] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants With On-treatment Biochemical Flares During

## Follow-up Phase

End point title	FU Phase: Number of Participants With On-treatment Biochemical Flares During Follow-up Phase
End point description: Number of participants with on-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST $\geq 3 \times \text{ULN}$ and $\geq 3 \times \text{nadir}$ (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. On-treatment was defined as the time period during which the participant received any of the study drugs. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.	
End point type	Secondary
End point timeframe: FU phase: FU Week 1 up to FU Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	8	17	
Units: participants	2	0	2	

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants with Off-treatment Biochemical HBV Flares During Follow-up Phase

End point title	FU Phase: Number of Participants with Off-treatment Biochemical HBV Flares During Follow-up Phase
End point description: Number of participants with off-treatment biochemical HBV flares were reported. Biochemical flare was defined as first date of 2 consecutive visits with confirmed ALT and/or AST $\geq 3 \times \text{ULN}$ and $\geq 3 \times \text{nadir}$ (lowest value observed up to start of flare). Confirmed means that the criteria was fulfilled at 2 or more consecutive time points or at the last observed time point. Off-treatment was defined as the time period after stopping all study treatments (including NA). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.	
End point type	Secondary
End point timeframe: FU phase: FU Week 1 up to FU Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>	1	
Units: participants			0	

Notes:

[10] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[11] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

## Secondary: FU Phase: Number of Participants With Off-treatment Clinical Flares During Follow-up Phase

End point title	FU Phase: Number of Participants With Off-treatment Clinical Flares During Follow-up Phase
-----------------	--

End point description:

Clinical flares occurred either when a virologic flare (confirmed HBV DNA >peak threshold) & biochemical flare (ALT and/or AST  $\geq 3 \times \text{ULN}$  &  $\geq 3 \times \text{nadir}$  [lowest value observed during off-treatment period up to time point of meeting the flare criteria]) overlapped in time or when a biochemical flare started within 4 weeks following the end of a virologic flare. The HBV DNA thresholds were: 20,000 IU/mL, 2,000 IU/mL and 200 IU/mL. Confirmed means that criteria was fulfilled at 2 or more consecutive time points or at last observed time point. Off-treatment was defined as time period after stopping all study drugs (including NA). The start date of a clinical flare was minimum start date of virologic flare and biochemical flare. Treated analysis set was used. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.

End point type	Secondary
End point timeframe:	
FU phase: FU Week 1 up to FU Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>	1	
Units: participants			0	

Notes:

[12] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[13] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

### Secondary: FU Phase: Percentage of Participants Who Required NA Re-treatment During Follow-Up Phase

End point title	FU Phase: Percentage of Participants Who Required NA Re-treatment During Follow-Up Phase
-----------------	--

End point description:

Percentage of participants who required NA re-treatment during follow-up phase were reported. A responder was defined as a participant who met the criteria for NA re-treatment at any time during follow-up, for those participants who met the NA treatment completion criteria at any time during the study and actually stopped NA treatment. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Here, N=0 signifies that data were not collected and analysed for participants who stopped NA at the end of treatment.

End point type	Secondary
End point timeframe:	
FU phase: FU Week 1 up to FU Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	0 <sup>[14]</sup>	0 <sup>[15]</sup>	1	
Units: percentage of participants				
number (not applicable)			0	

Notes:

[14] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

[15] - N=0 signifies data were not collected & analysed for participants who stopped NA at end of treatment

## Statistical analyses

No statistical analyses for this end point

### Secondary: FU phase: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 1) at Follow-up Week 48

End point title	FU phase: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 1) at Follow-up Week 48
-----------------	---

End point description:

Percentage of participants with sustained (reduction) HBsAg response (per Definition 1) were reported. Sustained HBsAg response (definition 1) was defined as: For participants with FU Week 48 data: participants who had a >1 log<sub>10</sub> decline from baseline in HBsAg and HBsAg <000 IU/mL at FU Week 48. For participants without FU Week 48 data: participants who had a HBsAg decline from baseline of >2 log<sub>10</sub> at FU Week 24 or >1.5 log<sub>10</sub> at FU Week 36 (most recent value used) and had HBsAg <1000 IU/mL at the last available timepoint.

End point type	Secondary
End point timeframe:	
At FU Phase Week 48	

<b>End point values</b>	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegI FN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	7	17	
Units: percentage of participants				
number (not applicable)	53.85	57.1	70.6	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 3) at Follow-up Week 48

End point title	Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 3) at Follow-up Week 48
-----------------	---

End point description:

Percentage of participants with sustained (reduction) HBsAg response (per definition 3) were reported. Sustained HBsAg response (per Definition 3) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2 and had an HBsAg <1000 IU/mL at the last available timepoint. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
At Follow up Phase Week 48	

<b>End point values</b>	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegI FN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	7	17	
Units: percentage of participants				
number (not applicable)	42.3	28.6	52.9	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 2) at Follow-up Week 48

End point title	Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 2) at Follow-up Week 48
End point description: Percentage of participants with sustained (reduction) HBsAg response (per Definition 2) were reported. Sustained HBsAg response (per Definition 2) was defined as: for participants with a >1 log decline in HBsAg from baseline at last follow-up visit: Among the most recent three visits, the difference between log10 HBsAg at 2 of 3 last visit and 1 of 3 last visit was <0.2, and the difference between log10 HBsAg at 3 of 3 last visit and 1 of 3 last visit was <0.2. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.	
End point type	Secondary
End point timeframe: At FU Phase Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	7	17	
Units: percentage of participants				
number (not applicable)	65.4	42.9	70.6	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 4) at Follow-up Week 48

End point title	Percentage of Participants Who Achieved Reduction (Sustained) in HBsAg Response (Per Definition 4) at Follow-up Week 48
-----------------	---

End point description:

Percentage of participants with sustained (reduction) HBsAg response per

Definition 4 were reported. Sustained HBsAg response (per Definition 4) was defined as stable level, decreasing level, and increasing level. Stable level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was within 0.2 log10.

Decreasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was less than -0.2 log10. Increasing level: when HBsAg change from consolidation week 12 to last available follow-up timepoint was more than 0.2 log10.

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
At Follow up Phase Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegIFN- alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	7	17	
Units: percentage of participants				
number (not applicable)				
Stable: within +/-0.2 log10 IU/mL	0	14.3	11.8	
Decreased: <0.2 log10 IU/mL	19.2	14.3	17.6	
Increased: > +0.2 log10 IU/mL	76.9	71.4	70.6	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With HBsAg Seroclearance at Follow-up Week 48

End point title	Percentage of Participants With HBsAg Seroclearance at Follow-up Week 48
-----------------	--

End point description:

Percentage of Participants with HBsAg Seroclearance were reported. HBsAg

seroclearance was defined as (quantitative) HBsAg level <LLOQ (<0.05 IU/mL).

Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
At Follow up Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegI FN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	26	6	17	
Units: percentage of participants				
number (not applicable)	11.5	16.7	11.8	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with HBeAg Seroclearance at Follow-up Week 48

End point title	Percentage of Participants with HBeAg Seroclearance at Follow-up Week 48
End point description: Percentage of participants with HBeAg seroclearance were reported. HBeAg seroclearance was defined as (quantitative) HBeAg levels <LLOQ (<0.11 IU/mL). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.	
End point type	Secondary
End point timeframe: At Follow up Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ- 6379+NA+PegI FN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN- alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	25	6	17	
Units: percentage of participants				
number (not applicable)	28.0	33.3	17.6	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with HBsAg Seroconversion

End point title	Percentage of Participants with HBsAg Seroconversion
End point description: Seroconversion of HBsAg was defined as having achieved HBsAg seroclearance (defined as quantitative HBsAg <LLOQ [<0.05 IU/mL]) and appearance of anti-HBs antibodies (defined as a baseline anti-HBs antibodies [quantitative] <LLOQ [<5	

milli-international units per milliliter (mIU/mL)] and a post-baseline assessment  $\geq$  LLOQ [ $\geq 5$  mIU/mL]). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint and "n" (number analysed) signifies participants evaluable at specified timepoints and n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
End point timeframe:	
IP Week 24; CP: Week 12, FU phase: Week 48	

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	25	7	15	24
Units: percentage of participants				
number (not applicable)				
IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0)	0	0	0	99999
CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)	99999	99999	99999	8.3
FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15)	99999	99999	99999	99999

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	15	25	7
Units: percentage of participants				
number (not applicable)				
IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0)	99999	99999	99999	99999
CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)	33.3	6.7	99999	99999
FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15)	99999	99999	12.0	99999

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	15			
Units: percentage of participants				

number (not applicable)				
IP: Week 24 (n=25, 7, 15, 0, 0, 0, 0, 0, 0)	99999			
CP: Week 12 (n=0, 0, 0, 24,6,15, 0, 0, 0)	99999			
FU phase Week 48 (n=0, 0, 0, 0, 0, 0, 25, 7, 15)	6.7			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with HBeAg Seroconversion

End point title	Percentage of Participants with HBeAg Seroconversion
-----------------	--

End point description:

Percentage of participants with HBeAg seroconversion were reported.

Seroconversion of HBeAg was defined as having achieved HBeAg seroclearance (defined as [quantitative] HBeAg <LLOQ [ $<0.11$  IU/mL]) together with appearance of anti-HBe antibodies (defined as a baseline anti-HBe antibodies [qualitative] with a "negative" result and a post-baseline assessment with "positive" result). Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Data were planned to be collected and analysed for CP and FU phase only. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:

CP: Week 12; FU phase: FU Week 48

End point values	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegI	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegI FN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	21	6	11	22
Units: percentage of participants				
number (not applicable)				
CP: Week 12 (n=21, 6,11, 0, 0, 0)	0	16.7	9.1	99999
FU phase week 48 (n=0, 0, 0, 22, 7, 11)	99999	99999	99999	18.2

End point values	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	11		
Units: percentage of participants				

number (not applicable)				
CP: Week 12 (n=21, 6,11, 0, 0, 0)	99999	99999		
FU phase week 48 (n=0, 0, 0, 22, 7, 11)	20.0	27.3		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline over time in HBsAg Levels

End point title	Change from baseline over time in HBsAg Levels
-----------------	--

End point description:

Change from baseline over time in HBsAg levels at specified timepoints were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36 (n=13,0,1,0,0,0,0,0)	-2.29 (± 0.211)	99999 (± 99999)	-4.08 (± 99999)	99999 (± 99999)
CP: Week 12(n=0,0,0,25,7,17,0,0,0)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	-3.51 (± 0.275)
FU phase: Week 48(n=0,0,0,0,0,0,26,8,17)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	6
Units: log10 IU/mL				
arithmetic mean (standard error)				

IP: Week 36 (n=13,0,1,0,0,0,0,0,0)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)
CP: Week 12(n=0,0,0,25,7,17,0,0,0)	-4.17 (± 0.444)	-3.53 (± 0.285)	99999 (± 99999)	99999 (± 99999)
FU phase: Week 48(n=0,0,0,0,0,0,26,8,17)	99999 (± 99999)	99999 (± 99999)	-2.41 (± 0.364)	-3.14 (± 0.747)

<b>End point values</b>	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36 (n=13,0,1,0,0,0,0,0,0)	99999 (± 99999)			
CP: Week 12(n=0,0,0,25,7,17,0,0,0)	99999 (± 99999)			
FU phase: Week 48(n=0,0,0,0,0,0,26,8,17)	-2.82 (± 0.425)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline over time in HBeAg Levels

End point title	Change from baseline over time in HBeAg Levels
End point description:	
Change from baseline over time in HBeAg levels were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, "n"=number of subjects analysed at specified categories n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.	
End point type	Secondary
End point timeframe:	
Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48	

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	24
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36(n=12,0,1,0,0,0,0,0)	-1.66 (± 0.159)	99999 (± 99999)	-2.85 (± 99999)	99999 (± 99999)
CP: Week 12(n=0,0,0,24,7,17,0,0,0)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	-2.14 (± 0.146)
FU phase: Week 48(n=0,0,0,0,0,0,25,8,17)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	25	8
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36(n=12,0,1,0,0,0,0,0)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)
CP: Week 12(n=0,0,0,24,7,17,0,0,0)	-2.39 (± 0.162)	-2.22 (± 0.234)	99999 (± 99999)	99999 (± 99999)
FU phase: Week 48(n=0,0,0,0,0,0,25,8,17)	99999 (± 99999)	99999 (± 99999)	-2.45 (± 0.243)	-2.59 (± 0.508)

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36(n=12,0,1,0,0,0,0,0)	99999 (± 99999)			
CP: Week 12(n=0,0,0,24,7,17,0,0,0)	99999 (± 99999)			
FU phase: Week 48(n=0,0,0,0,0,0,25,8,17)	-2.47 (± 0.278)			

## Statistical analyses

**Secondary: Change from Baseline Over Time in HBV DNA Levels**

End point title	Change from Baseline Over Time in HBV DNA Levels
-----------------	--

End point description:
------------------------

Change from baseline over time in HBV DNA Levels were reported. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this outcome measure and "n"(number analysed) signifies participants evaluable at specified timepoints. Here, 99999 at IP Week 36 category for Cohort 2 (Per PA 6) signifies that standard deviation was not estimable as only 1 participant was analysed. Here, "n"=number of subjects analysed at specified categories and n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:
----------------------

Baseline (Day 1 of IP), IP: Week 36; CP: Week 12; FU phase: Week 48
---

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36 (n=14,0,1,0,0,0,0,0)	-5.84 (± 0.427)	99999 (± 99999)	-6.99 (± 99999)	99999 (± 99999)
CP: Week 12(n=0,0,0,25,6,17,0,0,0)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	-6.29 (± 0.205)
FU phase: Week 48(n=0,0,0,0,0,0,26,6,17)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	17	26	8
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36 (n=14,0,1,0,0,0,0,0)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)
CP: Week 12(n=0,0,0,25,6,17,0,0,0)	-6.30 (± 0.350)	-6.07 (± 0.269)	99999 (± 99999)	99999 (± 99999)
FU phase: Week 48(n=0,0,0,0,0,0,26,6,17)	99999 (± 99999)	99999 (± 99999)	-6.79 (± 0.203)	-5.95 (± 0.563)

<b>End point values</b>	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: log10 IU/mL				
arithmetic mean (standard error)				
IP: Week 36 (n=14,0,1,0,0,0,0,0)	99999 (± 99999)			
CP: Week 12(n=0,0,0,25,6,17,0,0)	99999 (± 99999)			
FU phase: Week 48(n=0,0,0,0,0,0,26,6,17)	-6.70 (± 0.257)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Achieve First HBsAg Seroclearance

End point title	Time to Achieve First HBsAg Seroclearance
End point description:	
Time to achieve first HBsAg seroclearance (defined as quantitative HBsAg <LLOQ; HBsAg <0.05 IU/mL) were reported. Time to HBsAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of HBsAg seroclearance. Kaplan-Meier method was used for the estimation. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Here, 99999 signifies that that median [90% CI] data were not estimable due to low number of events. Per planned analysis data for this outcome measure was analysed per pooled cohorts only.	
End point type	Secondary
End point timeframe:	
From baseline (Day 1 of IP) to Follow up Week 48	

<b>End point values</b>	Cohort 1 (Prior PA 5): JNJ- 3989+JNJ- 6379+NA + PegIFN-alpha- 2a	Cohort 1 (Per PA 5): JNJ- 3989+ NA + PegIFN-alpha- 2a	Cohort 2 (Per PA 6): JNJ- 3989+ NA + PegIFN-alpha- 2a	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	27	8	19	
Units: weeks				
median (confidence interval 90%)	99999 (99999 to 99999)	99999 (6.1 to 99999)	99999 (99999 to 99999)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Achieve First HBV DNA <LLOQ

End point title	Time to Achieve First HBV DNA <LLOQ
-----------------	-------------------------------------

End point description:

Time to achieve first occurrence of HBV DNA < LLOQ (<20 IU/mL) were reported. Time to first occurrence of the HBV DNA < LLOQ was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBV DNA < LLOQ. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. Here 99999 signifies upper interval of [90% CI] data were not estimable due to low number of events.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day 1 of IP) to Follow up Week 48

End point values	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	27	8	19	
Units: weeks				
median (confidence interval 90%)	35.9 (28.1 to 52.1)	53.3 (12.1 to 99999)	38.1 (24.1 to 50.1)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Achieve First HBeAg Seroclearance

End point title	Time to Achieve First HBeAg Seroclearance
-----------------	---

End point description:

Time to achieve first occurrence of HBeAg seroclearance (HBeAg <LLOQ [ $<0.11$  IU/mL]) were reported. Time to first occurrence of the HBeAg seroclearance was defined as the number of days between the date of first study intervention intake and the date of the first occurrence of the HBeAg seroclearance. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Per planned analysis data for this outcome measure was analysed per pooled cohorts only. Here, 99999 signifies that Median and upper interval of [90% CI] data were not estimable due to low number of events.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day 1 of IP) to Follow up Week 48

End point values	Cohort 1 (Prior PA 5): JNJ-3989+JNJ-6379+NA + PegIFN-alpha-2a	Cohort 1 (Per PA 5): JNJ-3989+ NA + PegIFN-alpha-2a	Cohort 2 (Per PA 6): JNJ-3989+ NA + PegIFN-alpha-2a	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	27	8	19	
Units: weeks				
median (confidence interval 90%)	112 (96.1 to 99999)	100.3 (48.0 to 99999)	99999 (59.1 to 99999)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants with HBeAg Levels Below Different Cut-offs

End point title	Percentage of participants with HBeAg Levels Below Different Cut-offs
-----------------	---

End point description:

Percentage of participants with HBeAg levels below different cut-offs were reported. The cut-offs for HBeAg levels were : <LLOQ (<0.11 IU/mL), < 1 IU/mL, < 10 IU/mL, <100 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies participants who were evaluable for this endpoint. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: Week 36, CP: Week 12; FU phase: Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	8	19	24
Units: percentage of participants				
number (not applicable)				
IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0)	8.3	99999	0	99999
IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0)	25.0	99999	0	99999
IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0)	50.0	99999	100.0	99999
IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0)	100.0	99999	100.0	99999

CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0)	99999	99999	99999	12.5
CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	99999	99999	99999	37.5
CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	99999	99999	99999	75.0
CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	99999	99999	99999	95.8
FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17)	99999	99999	99999	99999
FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)	99999	99999	99999	99999
FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17)	99999	99999	99999	99999
FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17)	99999	99999	99999	99999

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	25	8
Units: percentage of participants				
number (not applicable)				
IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0,0)	99999	99999	99999	99999
CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0)	14.3	17.6	99999	99999
CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	14.3	47.1	99999	99999
CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	100.0	76.5	99999	99999
CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	100.0	94.1	99999	99999
FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17)	99999	99999	28.0	33.3
FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)	99999	99999	44.0	50.0
FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17)	99999	99999	80.0	83.3
FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17)	99999	99999	96.0	100

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-			
------------------	--	--	--	--

	alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: percentage of participants				
number (not applicable)				
IP Week 36: <0.11 IU/mL(n=12,0,1,0,0,0,0,0)	99999			
IP Week 36: <1 IU/mL (n=12,0,1,0,0,0,0,0)	99999			
IP Week 36: <10 IU/mL(n=12,0,1,0,0,0,0,0)	99999			
IP Week 36: <100 IU/mL(n=12,0,1,0,0,0,0,0)	99999			
CP Week 12: <0.11 IU/mL (n=0, 0, 0,24,7,17,0,0,0)	99999			
CP Week 12: <1 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	99999			
CP Week 12: <10 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	99999			
CP Week 12: <100 IU/mL(n=0, 0, 0,24,7,17,0,0,0)	99999			
FU Week 48: <0.11 IU/mL (n=0, 0, 0,0,0,0,25,6,17)	17.6			
FU Week 48: <1 IU/mL(n=0, 0, 0,0,0,0,25,6,17)	52.9			
FU Week 48: <10 IU/mL(n=0, 0, 0,0,0,0,25,6,17)	76.5			
FU Week 48: <100IU/mL(n=0, 0, 0,0,0,0,25,6,17)	100			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With HBsAg Levels Below Different Cut-offs

End point title	Percentage of Participants With HBsAg Levels Below Different Cut-offs
-----------------	---

End point description:

Percentage of participants with HBsAg levels below different cut-offs were reported. The cut-offs for HBsAg level were: <LLOQ (<0.05 IU/mL), <1 IU/mL, <10 IU/mL, <100 IU/mL, <1000 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"=number of subjects analysed at specified categories. n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: Week 36, CP: Week 12; FU phase: Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: percentage of participants				
number (not applicable)				
IP Week 36: <0.05 IU/mL(n=13,0,1,0,0,0,0,0)	0	99999	0	99999
IP Week 36: <1 IU/mL(n=13,0,1,0,0,0,0,0)	0	99999	0	99999
IP Week 36: <10 IU/mL(n=13,0,1,0,0,0,0,0)	0	99999	100.0	99999
IP Week 36: <100 IU/mL(n=13,0,1,0,0,0,0,0)	23.1	99999	100.0	99999
IP Week 36: <1000 IU/mL(n=13,0,1,0,0,0,0,0)	69.2	99999	100.0	99999
CP Week 12: <0.05 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999	99999	99999	8.0
CP Week 12: <1 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999	99999	99999	20.0
CP Week 12: <10 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999	99999	99999	40.0
CP Week 12: <100 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999	99999	99999	60.0
CP Week 12: <1000 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999	99999	99999	100.0
FU Week 48: <0.05 IU/mL(n=0,0,0,0,0,26,6,17)	99999	99999	99999	99999
FU Week 48: <1 IU/mL(n=0,0,0,0,0,26,6,17)	99999	99999	99999	99999
FU Week 48: <10 IU/mL(n=0,0,0,0,0,26,6,17)	99999	99999	99999	99999
FU Week 48: <100 IU/mL(n=0,0,0,0,0,26,6,17)	99999	99999	99999	99999
FU Week 48: <1000 IU/mL(n=0,0,0,0,0,26,6,17)	99999	99999	99999	99999

End point values	CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: percentage of participants				
number (not applicable)				
IP Week 36: <0.05 IU/mL(n=13,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <1 IU/mL(n=13,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <10 IU/mL(n=13,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <100 IU/mL(n=13,0,1,0,0,0,0,0)	99999	99999	99999	99999

IP Week 36: <1000 IU/mL(n=13,0,1,0,0,00,0,0)	99999	99999	99999	99999
CP Week 12: <0.05 IU/mL(n=0,0,0,25,7,17,0,0,0)	42.9	5.9	99999	99999
CP Week 12: <1 IU/mL(n=0,0,0,25,7,17,0,0,0)	42.9	23.5	99999	99999
CP Week 12: <10 IU/mL(n=0,0,0,25,7,17,0,0,0)	42.9	47.1	99999	99999
CP Week 12: <100 IU/mL(n=0,0,0,25,7,17,0,0,0)	71.4	76.5	99999	99999
CP Week 12: <1000 IU/mL(n=0,0,0,25,7,17,0,0,0)	100.0	94.1	99999	99999
FU Week 48: <0.05 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	11.5	16.7
FU Week 48: <1 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	11.5	33.3
FU Week 48: <10 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	19.2	50.0
FU Week 48: <100 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	26.9	50.0
FU Week 48: <1000 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	57.7	66.7

End point values	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN- alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: percentage of participants				
number (not applicable)				
IP Week 36: <0.05 IU/mL(n=13,0,1,0,0,0,0,0,0)	99999			
IP Week 36: <1 IU/mL(n=13,0,1,0,0,0,0,0,0)	99999			
IP Week 36: <10 IU/mL(n=13,0,1,0,0,0,0,0,0)	99999			
IP Week 36: <100 IU/mL(n=13,0,1,0,0,0,0,0,0)	99999			
IP Week 36: <1000 IU/mL(n=13,0,1,0,0,00,0,0)	99999			
CP Week 12: <0.05 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999			
CP Week 12: <1 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999			
CP Week 12: <10 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999			
CP Week 12: <100 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999			
CP Week 12: <1000 IU/mL(n=0,0,0,25,7,17,0,0,0)	99999			
FU Week 48: <0.05 IU/mL(n=0,0,0,0,0,0,26,6,17)	11.8			
FU Week 48: <1 IU/mL(n=0,0,0,0,0,0,26,6,17)	17.6			
FU Week 48: <10 IU/mL(n=0,0,0,0,0,0,26,6,17)	29.4			

FU Week 48: <100 IU/mL(n=0,0,0,0,0,26,6,17)	47.1			
FU Week 48: <1000 IU/mL(n=0,0,0,0,0,26,6,17)	76.5			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With HBV DNA Levels Below Different Cut-offs

End point title	Percentage of Participants With HBV DNA Levels Below Different Cut-offs
-----------------	---

End point description:

Percentage of participants with HBV DNA levels below cut-offs were reported.

The cut-offs for HBV DNA were as follows: <LLOQ (<20 IU/mL) for target detected or not detected(Td and Nd), < LLOQ for target not detected (TNd), and < LLOQ for target detected (TD), <60 IU/mL, <100 IU/mL, <200 IU/mL, <1000 IU/mL, <2000 IU/mL, <20000 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here, "n"(number of participants analysed) signifies participants analysed at specified categories. Here, n=0, and 99999 signify that data were not collected and analysed as that timepoint was not applicable to the respective arm.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: Week 36; CP: Week 12; FU phase: Week 48

End point values	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	14	0 <sup>[16]</sup>	1	25
Units: percentage of participants				
number (not applicable)				
IP Week 36:<LLOQ Td & Nd (n=14,0,1,0,0,0,0,0)	42.9		100.0	99999
IP Week 36:<LLOQ for TNd(n=14,0,1,0,0,0,0,0)	0		0	99999
IP Week 36:<LLOQ for Td(14,0,1,0,0,0,0,0)	42.9		100.0	99999
IP Week 36:<60 IU/mL(14,0,1,0,0,0,0,0)	64.3		100.0	99999
IP Week 36:<100 IU/mL (14,0,1,0,0,0,0,0)	71.4		100.0	99999
IP Week 36:<200 IU/mL (14,0,1,0,0,0,0,0)	78.6		100.0	99999
IP Week 36:<1000 IU/mL(n=14,0,1,0,0,0,0,0)	92.9		100.0	99999
IP Week 36:<2000 IU/mL(n=14,0,1,0,0,0,0,0)	92.9		100.0	99999
IP Week 36:<20000 IU/mL(n=14,0,1,0,0,0,0,0)	92.9		100.0	99999

CP Week 12: <LLOQ: Td & Nd (n=0,0,0,25,6,17,0,0,0)	99999		99999	32.0
CP Week 12: <LLOQ for TNd (n=0,0,0,25,6,17,0,0,0)	99999		99999	0
CP Week 12: <LLOQ for Td (n=0,0,0,25,6,17,0,0,0)	99999		99999	32.0
CP Week 12: <60 IU/mL (n=0,0,0,25,6,17,0,0,0)	99999		99999	76.0
CP Week 12: <100 IU/mL (n=0,0,0,25,6,17,0,0,0)	99999		99999	92.0
CP Week 12: <200 IU/mL (n=0,0,0,25,6,17,0,0,0)	99999		99999	96.0
CP Week 12: <1000 IU/mL (n=0,0,0,25,6,17,0,0,0)	99999		99999	100.0
CP Week 12: <2000 IU/mL (n=0,0,0,25,6,17,0,0,0)	99999		99999	100.0
CP Week 12: <20000 IU/mL (n=0,0,0,25,6,17,0,0,0)	99999		99999	100.0
FU Week 48: <LLOQ Td & Nd (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <LLOQ for TNd (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <LLOQ for Td (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <60 IU/mL (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <100 IU/mL (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <200 IU/mL (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <1000 IU/mL (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <2000 IU/mL (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999
FU Week 48: <20000 IU/mL (n=0,0,0,0,0,0,26,6,17)	99999		99999	99999

Notes:

[16] - No participant was available for the analysis.

End point values	CP: Cohort 1 (Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+ PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	17	26	8
Units: percentage of participants				
number (not applicable)				
IP Week 36: <LLOQ Td & Nd (n=14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <LLOQ for TNd (n=14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <LLOQ for Td (14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <60 IU/mL (14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <100 IU/mL (14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <200 IU/mL (14,0,1,0,0,0,0,0)	99999	99999	99999	99999

IP Week 36: <1000 IU/mL(n=14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <2000 IU/mL(n=14,0,1,0,0,0,0,0)	99999	99999	99999	99999
IP Week 36: <20000 IU/mL(n=14,0,1,0,0,0,0,0)	99999	99999	99999	99999
CP Week 12: <LLOQ:Td & Nd(n=0,0,0,25,6,17,0,0,0)	33.3	29.4	99999	99999
CP Week 12: <LLOQ for TNd(n=0,0,0,25,6,17,0,0,0)	0	0	99999	99999
CP Week 12: <LLOQ for Td(n=0,0,0,25,6,17,0,0,0)	33.3	29.4	99999	99999
CP Week 12: <60 IU/mL(n=0,0,0,25,6,17,0,0,0)	50.0	58.8	99999	99999
CP Week 12: <100 IU/mL(n=0,0,0,25,6,17,0,0,0)	83.3	64.7	99999	99999
CP Week 12: <200 IU/mL(n=0,0,0,25,6,17,0,0,0)	83.3	82.4	99999	99999
CP Week 12: <1000 IU/mL(n=0,0,0,25,6,17,0,0,0)	100.0	94.1	99999	99999
CP Week 12: <2000 IU/mL(n=0,0,0,25,6,17,0,0,0)	100.0	100.0	99999	99999
CP Week 12: <20000 IU/mL(n=0,0,0,25,6,17,0,0,0)	100.0	100.0	99999	99999
FU Week 48: <LLOQ Td & Nd(n=0,0,0,0,0,0,26,6,17)	99999	99999	84.6	50.0
FU Week 48: <LLOQ for TNd (n=0,0,0,0,0,0,26,6,17)	99999	99999	34.6	16.7
FU Week 48: <LLOQ for Td(n=0,0,0,0,0,0,26,6,17)	99999	99999	50.0	33.3
FU Week 48: <60 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	92.3	50.0
FU Week 48: <100 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	100.0	66.7
FU Week 48: <200 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	100.0	83.3
FU Week 48: <1000 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	100.0	83.3
FU Week 48: <2000 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	100.0	83.3
FU Week 48: <20000 IU/mL(n=0,0,0,0,0,0,26,6,17)	99999	99999	100.0	100.0

<b>End point values</b>	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: percentage of participants				
number (not applicable)				
IP Week 36: <LLOQ Td & Nd (n=14,0,1,0,0,0,0,0)	99999			
IP Week 36: <LLOQ for TNd(n=14,0,1,0,0,0,0,0)	99999			
IP Week 36: <LLOQ for Td(14,0,1,0,0,0,0,0)	99999			

IP Week 36: <60 IU/mL(14,0,1,0,0,0,0,0)	99999			
IP Week 36: <100 IU/mL (14,0,1,0,0,0,0,0)	99999			
IP Week 36: <200 IU/mL (14,0,1,0,0,0,0,0)	99999			
IP Week 36: <1000 IU/mL(n=14,0,1,0,0,0,0,0)	99999			
IP Week 36: <2000 IU/mL(n=14,0,1,0,0,0,0,0)	99999			
IP Week 36: <20000 IU/mL(n=14,0,1,0,0,0,0,0)	99999			
CP Week 12: <LLOQ:Td & Nd(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <LLOQ for TNd(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <LLOQ for Td(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <60 IU/mL(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <100 IU/mL(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <200 IU/mL(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <1000 IU/mL(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <2000 IU/mL(n=0,0,0,25,6,17,0,0,0)	99999			
CP Week 12: <20000 IU/mL(n=0,0,0,25,6,17,0,0,0)	99999			
FU Week 48: <LLOQ Td & Nd(n=0,0,0,0,0,0,26,6,17)	88.2			
FU Week 48: <LLOQ for TNd (n=0,0,0,0,0,0,26,6,17)	17.6			
FU Week 48: <LLOQ for Td(n=0,0,0,0,0,0,26,6,17)	70.6			
FU Week 48: <60 IU/mL(n=0,0,0,0,0,0,26,6,17)	94.1			
FU Week 48: <100 IU/mL(n=0,0,0,0,0,0,26,6,17)	100.0			
FU Week 48: <200 IU/mL(n=0,0,0,0,0,0,26,6,17)	100.0			
FU Week 48: <1000 IU/mL(n=0,0,0,0,0,0,26,6,17)	100.0			
FU Week 48: <2000 IU/mL(n=0,0,0,0,0,0,26,6,17)	100.0			
FU Week 48: <20000 IU/mL(n=0,0,0,0,0,0,26,6,17)	100.0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with Virologic Breakthrough

End point title	Percentage of Participants with Virologic Breakthrough
-----------------	--

End point description:

Percentage of participants with virologic breakthrough on treatment were

reported. Virological breakthrough was defined as confirmed on-treatment HBV DNA increase by >1 log10 IU/mL from nadir level (lowest level reached during treatment) in participants who did not have on-treatment HBV DNA level < LLOQ (<20 IU/mL) or confirmed on-treatment HBV DNA level >200 IU/mL in participants who had on-treatment HBV DNA level <LLOQ of the HBV DNA assay. Confirmed HBV DNA increase/level means that the criterion was fulfilled at 2 or more consecutive time points or at the last observed on-treatment time point. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA.

End point type	Secondary
----------------	-----------

End point timeframe:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

<b>End point values</b>	IP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 1 (Per PA 5): JNJ-3989 + NA + PegIFN-alpha-2a	IP:Cohort 2(Per PA 6): JNJ-3989+NA+PegIFN-alpha-2a	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	27	8	19	25
Units: percentage of participants				
number (not applicable)	3.7	12.5	0	0

<b>End point values</b>	CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	7	17	26	8
Units: percentage of participants				
number (not applicable)	0	0	0	50.0

<b>End point values</b>	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a			
Subject group type	Subject analysis set			
Number of subjects analysed	17			
Units: percentage of participants				
number (not applicable)	0			

## Statistical analyses

No statistical analyses for this end point

**Secondary: Percentage of Participants Who Reached HBV DNA Undetectability After Re-start of NA Treatment During Follow-up**

End point title	Percentage of Participants Who Reached HBV DNA Undetectability After Re-start of NA Treatment During Follow-up
End point description: Percentage of participants who reached HBV DNA undetectability after re-start of NA treatment during follow-up were reported. Undetectability of HBV DNA was defined as HBV DNA<LLOQ that is <20 IU/mL. Treated analysis set included all participants who received at least 1 dose of study treatment within this ISA. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint.	
End point type	Secondary
End point timeframe: FU phase: FU Week 1 up to FU Week 48	

End point values	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	27	8	19	
Units: percentage of participants				
number (not applicable)	0	0	0	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])**

End point title	Maximum Observed Plasma Concentration (Cmax) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
End point description: Cmax of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Noncompartmental analysis were conducted to analyze Cmax JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who had received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.	
End point type	Secondary
End point timeframe: IP : Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on IP Week 24; CP: Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on CP Week 8	

End point values	Induction phase	Consolidation phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	8	6		
Units: nanogram per milliliters (ng/mL)				
arithmetic mean (standard deviation)				
JNJ-73763976	1376 (± 1266)	700 (± 227)		
JNJ-73763924	279 (± 308)	135 (± 39.9)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Reach the Maximum Observed Plasma Concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

End point title	Time to Reach the Maximum Observed Plasma Concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
-----------------	---

End point description:

Time to reach the maximum observed plasma concentration (tmax) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze tmax of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.

End point type	Secondary
----------------	-----------

End point timeframe:

IP : Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on IP Week 24; CP: Predose (0 hour), post dose on 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours on CP Week 8

End point values	Induction phase	Consolidation phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	8	6		
Units: hour				
median (full range (min-max))				
JNJ-73763976	5.53 (2.50 to 6.00)	3.99 (2.98 to 6.00)		
JNJ-73763924	4.00 (0.50 to 5.73)	2.99 (1.00 to 4.00)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

End point title	Plasma Concentration 24 Hours After Administration (C24h) of JNJ-73763989 (Molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
-----------------	--

#### End point description:

Plasma concentration 24 hours after administration (C24h) of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze C24h of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.

End point type	Secondary
----------------	-----------

#### End point timeframe:

IP: 24 hours post dose on Week 24 visit; CP: 24 hours post dose on Week 8 visit

End point values	Induction phase	Consolidation phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	6		
Units: ng/mL				
arithmetic mean (standard deviation)				
JNJ-73763976	315 (± 213)	381 (± 155)		
JNJ-73763924	36.9 (± 27.9)	54.7 (± 25.0)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours [AUC (0-24 hours)] of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])

End point title	Area Under the Plasma Concentration-time Curve From Time
-----------------	--

Zero to 24 Hours [AUC (0-24 hours)] of JNJ-73763989 (molecules: JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924])
--

**End point description:**

Area under the plasma concentration-time curve from time zero to 24hours (AUC<sub>0</sub> to 24h) of JNJ-73763989 (molecules:JNJ-73763976 [JNJ3976], JNJ-73763924 [JNJ-3924]) were reported. Non-compartmental analysis were conducted to analyze AUC<sub>0</sub> to 24h of JNJ-73763989 and its molecules. Pharmacokinetics analysis set (PK): included participants who have received at least 1 dose of any of the study interventions and had at least 1 valid blood sample drawn for PK analysis. Here "N" (Number of participants analysed) signifies the number of participants that were evaluable for this endpoint. Data for this endpoint was planned to be collected and analysed as pooled cohort in induction phase and consolidation phase only.

End point type	Secondary
----------------	-----------

**End point timeframe:**

IP: 24 hours post dose on Week 24 visit; CP: 24 hours post dose on Week 8 visit

End point values	Induction phase	Consolidation phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	6		
Units: nanograms*hour per milliliters (ng*h/mL)				
arithmetic mean (standard deviation)				
JNJ-73763976	19109 (± 12482)	12219 (± 3499)		
JNJ-73763924	3089 (± 1964)	2117 (± 639)		

**Statistical analyses**

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

IP: From Day 1 up to end of IP (up to Week 36 per PA 5; up to Week 52 prior to PA 5); CP: CP Week 1 up to CP Week 12; FU phase: FU Week 1 up to FU Week 48

Adverse event reporting additional description:

Safety analysis was based on safety analysis set which included all participants who received at least one dose of study intervention and were analysed according to the study intervention they actually received.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

### Reporting groups

Reporting group title	IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a
-----------------------	--

Reporting group description:

Per PA 5, participants received JNJ-3989 200 mg SC injection for Q4W plus NA (TAD 245 mg/TAF 25 mg) tablets orally QD in IP for 36 weeks.

Reporting group title	IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
-----------------------	--

Reporting group description:

Prior to PA 5, participants received JNJ-3989 200 mg SC injection for Q4W + JNJ-6379 250 mg tablets orally QD plus NA (TAD 245 mg/TAF 25 mg) tablet orally QD in IP for a RGT duration for >=36-weeks to <=52-weeks.

Reporting group title	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
-----------------------	--

Reporting group description:

After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

Reporting group title	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
-----------------------	--

Reporting group description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TAD 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

Reporting group title	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a
-----------------------	---

Reporting group description:

After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus JNJ-6379 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12 NA was stopped at FU W2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

Reporting group title	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
-----------------------	---

Reporting group description:

After completion of CP, all participants entered 48-Week FU phase and stopped treatment with JNJ-3989 plus NA (TAD 245 mg/TAF 25 mg) plus PegIFN-alpha2a. If NA treatment completion criteria was met at CP Week 12, NA treatment was stopped at FU Week 2, if NA treatment completion criteria was not met, NA (TAD 245 mg/TAF 25 mg) was continued till the end of FU phase.

Reporting group title	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a
-----------------------	--

Reporting group description:

After completion of IP, participants entered in 12 week CP and received JNJ-3989 200 mg SC Q4W plus JNJ-6379 250 tablets QD plus NA (either TAD 250 mg or TAF

25 mg) tablet orally QD from CP Week 1 to 12 and PegIFN-alpha-2a 180 mcg SC injection was added to their treatment regimen from IP Week 36 for 12 weeks.

Reporting group title	IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a
-----------------------	--

Reporting group description:

Participants enrolled as per PA 6, received JNJ-3989 200 mg SC for Q4W plus NA (TAD 250 mg/TAF 25 mg) tablet orally QD in IP for 36 weeks.

Reporting group title	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
-----------------------	--

Reporting group description:

After completion of IP, participants entered in 12-week CP and received JNJ-3989 200 mg SC injection Q4W + NA (TDF 245 mg/TAF 25 mg) tablets orally QD from CP Week 1 to 12 and PegIFN-alpha2a 180 mcg SC QW was added to their treatment regimen from IP Week 36 for 12 weeks.

Serious adverse events	IP: Cohort 1-Per PA 5: JNJ-3989 + NA + PegIFN-alpha-2a	IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Pregnancy, puerperium and perinatal conditions			
Ectopic Pregnancy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989+ JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 1: JNJ-3989 + NA + PegIFN-alpha-2a
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Pregnancy, puerperium and perinatal conditions			
Ectopic Pregnancy			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	CP:Cohort 1(Prior PA 5):JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a	CP: Cohort 1(Per PA 5): JNJ-3989+NA+ PegIFN-alpha-2a
------------------------	--	--	--

Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Pregnancy, puerperium and perinatal conditions			
Ectopic Pregnancy			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	IP: Cohort 1-Per PA5: JNJ-3989 + NA + PegIFN-alpha-2a	IP: Cohort 1-prior PA5: JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	FU: Cohort 2 (Per PA6): JNJ-3989 + NA + PegIFN-alpha-2a
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 8 (100.00%)	19 / 27 (70.37%)	11 / 17 (64.71%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Haemangioma of Liver			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Hyperthermia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 8 (25.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	3	1	0
Chills			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 27 (7.41%)	0 / 17 (0.00%)
occurrences (all)	0	3	0
Injection Site Erythema			

subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Injection Site Bruising			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Influenza Like Illness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Injection Site Pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	2	0	0
Injection Site Pruritus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injection Site Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injection Site Reaction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injury Associated with Device			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 8 (12.50%)	1 / 27 (3.70%)	1 / 17 (5.88%)
occurrences (all)	1	2	1
Pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Non-Cardiac Chest Pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Temperature Intolerance			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			

Seasonal Allergy subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 3	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Mite Allergy subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Food Allergy subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Reproductive system and breast disorders Vaginal Haemorrhage subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 27 (3.70%) 1	2 / 17 (11.76%) 4
Epistaxis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Dyspnoea Exertional subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Dry Throat subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	2 / 17 (11.76%) 4
Allergic Sinusitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Respiratory Tract Congestion			

subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Rhinitis Allergic			
subjects affected / exposed	1 / 8 (12.50%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	1	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Sinus Congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Productive Cough			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Depressed Mood			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Apathy			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Anxiety Disorder			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	0 / 8 (0.00%)	8 / 27 (29.63%)	1 / 17 (5.88%)
occurrences (all)	0	13	1
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 8 (0.00%)	2 / 27 (7.41%)	0 / 17 (0.00%)
occurrences (all)	0	4	0
Blood Creatine Phosphokinase Increased			

subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Blood Glucose Increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Body Temperature Increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Glucose Urine Present			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Liver Scan Abnormal			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Ultrasound Liver Abnormal			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
White Blood Cell Count Decreased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Weight Decreased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Neutrophil Count Decreased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Head Injury			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Skin Wound			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Skin Laceration subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 27 (3.70%) 1	1 / 17 (5.88%) 1
Ligament Sprain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Sinus Tachycardia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Nervous system disorders Amnestic Disorder subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Neuropathy Peripheral subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Headache subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 3	5 / 27 (18.52%) 10	1 / 17 (5.88%) 2
Dizziness Postural subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Blood and lymphatic system disorders Leukopenia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Anaemia			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Neutropenia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Ear and labyrinth disorders Ear Pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Eye disorders Cataract subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Conjunctival Hyperaemia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Visual Impairment subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Myopia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Eye Pruritus subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 27 (3.70%) 1	0 / 17 (0.00%) 0
Gastrointestinal disorders Abdominal Discomfort subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Aphthous Ulcer subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 2
Abdominal Pain Upper			

subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Abdominal Pain Lower			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Abdominal Pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Abdominal Distension			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Dental Caries			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal Reflux Disease			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Food Poisoning			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 27 (7.41%)	0 / 17 (0.00%)
occurrences (all)	0	2	0
Diarrhoea			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Large Intestine Polyp			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Nausea			

subjects affected / exposed	3 / 8 (37.50%)	4 / 27 (14.81%)	0 / 17 (0.00%)
occurrences (all)	3	4	0
Mouth Ulceration			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Rectal Haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Rash Maculo-Papular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Skin Irritation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Skin Ulcer			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			

Pain in Extremity			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	1	0	1
Muscular Weakness			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Muscle Spasms			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Limb Mass			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Back Pain			
subjects affected / exposed	1 / 8 (12.50%)	2 / 27 (7.41%)	0 / 17 (0.00%)
occurrences (all)	1	2	0
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Aspergilloma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Acarodermatitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Lower Respiratory Tract Infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Carbuncle			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			

subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Covid-19			
subjects affected / exposed	2 / 8 (25.00%)	2 / 27 (7.41%)	0 / 17 (0.00%)
occurrences (all)	2	2	0
Hepatitis B			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 8 (0.00%)	1 / 27 (3.70%)	0 / 17 (0.00%)
occurrences (all)	0	1	0
Lower Respiratory Tract Infection Viral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	2 / 27 (7.41%)	2 / 17 (11.76%)
occurrences (all)	0	2	2
Oral Herpes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Periodontitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	0	1
Respiratory Tract Infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	1	0	0
Urinary Tract Infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0
Viral Infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 27 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0	0

Respiratory Tract Infection Viral subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 27 (3.70%) 1	1 / 17 (5.88%) 3
Sinusitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Rhinitis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1
Metabolism and nutrition disorders Decreased Appetite subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	2 / 27 (7.41%) 2	0 / 17 (0.00%) 0
Iron Deficiency subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	0 / 17 (0.00%) 0
Vitamin B12 Deficiency subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 27 (0.00%) 0	1 / 17 (5.88%) 1

<b>Non-serious adverse events</b>	CP: Cohort 2 (Per PA 6): JNJ-3989 + NA + PegIFN-alpha-2a	FU: Cohort 1: JNJ- 3989+ JNJ- 6379+NA+PegIFN- alpha-2a	FU: Cohort 1: JNJ- 3989 + NA + PegIFN-alpha-2a
Total subjects affected by non-serious adverse events subjects affected / exposed	13 / 17 (76.47%)	15 / 26 (57.69%)	5 / 8 (62.50%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Haemangioma of Liver subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
General disorders and administration site conditions Hyperthermia subjects affected / exposed occurrences (all)  Fatigue	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0

subjects affected / exposed	4 / 17 (23.53%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	4	0	1
Chills			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Asthenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Injection Site Erythema			
subjects affected / exposed	3 / 17 (17.65%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Injection Site Bruising			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Influenza Like Illness			
subjects affected / exposed	2 / 17 (11.76%)	2 / 26 (7.69%)	0 / 8 (0.00%)
occurrences (all)	2	2	0
Injection Site Pain			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injection Site Pruritus			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Injection Site Rash			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injection Site Reaction			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	5	0	0
Injury Associated with Device			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	3 / 17 (17.65%)	1 / 26 (3.85%)	1 / 8 (12.50%)
occurrences (all)	4	2	1
Pain			

subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Non-Cardiac Chest Pain subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Temperature Intolerance subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Immune system disorders Seasonal Allergy subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 26 (3.85%) 1	0 / 8 (0.00%) 0
Mite Allergy subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Food Allergy subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Reproductive system and breast disorders Vaginal Haemorrhage subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 26 (3.85%) 1	0 / 8 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Dyspnoea Exertional subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Dry Throat subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Cough			

subjects affected / exposed	0 / 17 (0.00%)	2 / 26 (7.69%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
Allergic Sinusitis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory Tract Congestion			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Rhinitis Allergic			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sinus Congestion			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Productive Cough			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Depressed Mood			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Apathy			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Anxiety Disorder			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	4 / 17 (23.53%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	6	0	0
Aspartate Aminotransferase Increased			
subjects affected / exposed	2 / 17 (11.76%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Blood Creatine Phosphokinase Increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Blood Glucose Increased			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Body Temperature Increased			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Glucose Urine Present			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	3
Liver Scan Abnormal			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Ultrasound Liver Abnormal			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
White Blood Cell Count Decreased			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Weight Decreased			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neutrophil Count Decreased			

subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Injury, poisoning and procedural complications			
Head Injury			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin Wound			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin Laceration			
subjects affected / exposed	0 / 17 (0.00%)	1 / 26 (3.85%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Ligament Sprain			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Sinus Tachycardia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Amnestic Disorder			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neuropathy Peripheral			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Dizziness Postural			

subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 17 (0.00%)	2 / 26 (7.69%)	0 / 8 (0.00%)
occurrences (all)	0	3	0
Anaemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 17 (5.88%)	1 / 26 (3.85%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Thrombocytopenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Ear Pain			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Conjunctival Hyperaemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Visual Impairment			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Myopia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye Pruritus			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			

Abdominal Discomfort			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Aphthous Ulcer			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal Pain Upper			
subjects affected / exposed	1 / 17 (5.88%)	1 / 26 (3.85%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Abdominal Pain Lower			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal Pain			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Abdominal Distension			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dental Caries			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal Reflux Disease			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Food Poisoning			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 17 (5.88%)	1 / 26 (3.85%)	0 / 8 (0.00%)
occurrences (all)	1	1	0

Diarrhoea			
subjects affected / exposed	0 / 17 (0.00%)	1 / 26 (3.85%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Large Intestine Polyp			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Mouth Ulceration			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rectal Haemorrhage			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Rash Maculo-Papular			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin Irritation			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 26 (3.85%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Skin Ulcer			

subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Musculoskeletal and connective tissue disorders Pain in Extremity subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Muscular Weakness subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Muscle Spasms subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	1 / 8 (12.50%) 1
Limb Mass subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Back Pain subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 26 (3.85%) 1	0 / 8 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Infections and infestations Aspergilloma subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Acarodermatitis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Lower Respiratory Tract Infection			

subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Carbuncle			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Covid-19			
subjects affected / exposed	0 / 17 (0.00%)	7 / 26 (26.92%)	1 / 8 (12.50%)
occurrences (all)	0	7	1
Hepatitis B			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Lower Respiratory Tract Infection Viral			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 17 (0.00%)	4 / 26 (15.38%)	0 / 8 (0.00%)
occurrences (all)	0	5	0
Oral Herpes			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory Tract Infection			
subjects affected / exposed	1 / 17 (5.88%)	0 / 26 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Urinary Tract Infection subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	2 / 8 (25.00%) 2
Viral Infection subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	1 / 8 (12.50%) 1
Respiratory Tract Infection Viral subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Rhinitis subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 26 (3.85%) 1	0 / 8 (0.00%) 0
Metabolism and nutrition disorders Decreased Appetite subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0
Iron Deficiency subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	1 / 8 (12.50%) 1
Vitamin B12 Deficiency subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 26 (0.00%) 0	0 / 8 (0.00%) 0

<b>Non-serious adverse events</b>	CP: Cohort 1(Prior PA 5): JNJ-3989+JNJ-6379+NA+PegIFN-alpha-2a	IP: Cohort 2 - Per PA 6: JNJ-3989 + NA + PegIFN-alpha-2a	CP: Cohort 1(Per PA 5): JNJ-3989+NA+PegIFN-alpha-2a
Total subjects affected by non-serious adverse events subjects affected / exposed	21 / 25 (84.00%)	15 / 19 (78.95%)	7 / 7 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Haemangioma of Liver			

subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Hyperthermia			
subjects affected / exposed	2 / 25 (8.00%)	0 / 19 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Fatigue			
subjects affected / exposed	5 / 25 (20.00%)	2 / 19 (10.53%)	2 / 7 (28.57%)
occurrences (all)	5	2	2
Chills			
subjects affected / exposed	2 / 25 (8.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Asthenia			
subjects affected / exposed	1 / 25 (4.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Injection Site Erythema			
subjects affected / exposed	3 / 25 (12.00%)	1 / 19 (5.26%)	1 / 7 (14.29%)
occurrences (all)	13	1	1
Injection Site Bruising			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Influenza Like Illness			
subjects affected / exposed	4 / 25 (16.00%)	0 / 19 (0.00%)	1 / 7 (14.29%)
occurrences (all)	6	0	1
Injection Site Pain			
subjects affected / exposed	1 / 25 (4.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Injection Site Pruritus			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injection Site Rash			
subjects affected / exposed	1 / 25 (4.00%)	0 / 19 (0.00%)	1 / 7 (14.29%)
occurrences (all)	3	0	1
Injection Site Reaction			

subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Injury Associated with Device subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	1 / 7 (14.29%) 1
Pyrexia subjects affected / exposed occurrences (all)	3 / 25 (12.00%) 3	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Non-Cardiac Chest Pain subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Temperature Intolerance subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	1 / 7 (14.29%) 1
Immune system disorders Seasonal Allergy subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Mite Allergy subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Food Allergy subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Reproductive system and breast disorders Vaginal Haemorrhage subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Epistaxis			

subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspnoea Exertional			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Dry Throat			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 25 (0.00%)	2 / 19 (10.53%)	1 / 7 (14.29%)
occurrences (all)	0	2	1
Allergic Sinusitis			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Respiratory Tract Congestion			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis Allergic			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Sinus Congestion			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Productive Cough			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 25 (4.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Depressed Mood			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Apathy			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Anxiety Disorder			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Investigations			
Alanine Aminotransferase Increased			
subjects affected / exposed	2 / 25 (8.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	2	3	0
Aspartate Aminotransferase Increased			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood Creatine Phosphokinase Increased			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood Alkaline Phosphatase Increased			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood Glucose Increased			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Body Temperature Increased			
subjects affected / exposed	2 / 25 (8.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Glucose Urine Present			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Liver Scan Abnormal			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ultrasound Liver Abnormal			

subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
White Blood Cell Count Decreased subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Weight Decreased subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Neutrophil Count Decreased subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications Head Injury subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Skin Wound subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Skin Laceration subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Ligament Sprain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Sinus Tachycardia subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	1 / 7 (14.29%) 1
Palpitations subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Nervous system disorders			

Amnestic Disorder subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Neuropathy Peripheral subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	5 / 25 (20.00%) 6	2 / 19 (10.53%) 2	0 / 7 (0.00%) 0
Dizziness Postural subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders			
Leukopenia subjects affected / exposed occurrences (all)	4 / 25 (16.00%) 6	0 / 19 (0.00%) 0	2 / 7 (28.57%) 2
Anaemia subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	7 / 25 (28.00%) 12	0 / 19 (0.00%) 0	2 / 7 (28.57%) 3
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 19 (0.00%) 0	1 / 7 (14.29%) 1
Ear and labyrinth disorders			
Ear Pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Eye disorders			
Cataract subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Conjunctival Hyperaemia subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Visual Impairment			

subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Myopia			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Eye Pruritus			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Aphthous Ulcer			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Abdominal Pain Upper			
subjects affected / exposed	0 / 25 (0.00%)	2 / 19 (10.53%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Abdominal Pain Lower			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal Pain			
subjects affected / exposed	1 / 25 (4.00%)	2 / 19 (10.53%)	0 / 7 (0.00%)
occurrences (all)	1	2	0
Abdominal Distension			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Constipation			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Dental Caries			
subjects affected / exposed	1 / 25 (4.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Haemorrhoids			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0

Gastrooesophageal Reflux Disease subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	2 / 19 (10.53%) 2	0 / 7 (0.00%) 0
Food Poisoning subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 2	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Large Intestine Polyp subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	2 / 19 (10.53%) 2	0 / 7 (0.00%) 0
Mouth Ulceration subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Rectal Haemorrhage subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders Eczema subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Rash Maculo-Papular			

subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	1 / 7 (14.29%) 1
Skin Irritation subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Skin Ulcer subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders Pain in Extremity subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 19 (5.26%) 1	2 / 7 (28.57%) 2
Muscular Weakness subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	1 / 7 (14.29%) 1
Muscle Spasms subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Limb Mass subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
Back Pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	2 / 19 (10.53%) 2	0 / 7 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 13	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Myalgia			

subjects affected / exposed occurrences (all)	2 / 25 (8.00%) 3	1 / 19 (5.26%) 1	0 / 7 (0.00%) 0
Infections and infestations			
Aspergilloma			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Acarodermatitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lower Respiratory Tract Infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Carbuncle			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Covid-19			
subjects affected / exposed	3 / 25 (12.00%)	4 / 19 (21.05%)	0 / 7 (0.00%)
occurrences (all)	3	4	0
Hepatitis B			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Lower Respiratory Tract Infection Viral			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oral Herpes			

subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Paronychia			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory Tract Infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary Tract Infection			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Viral Infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory Tract Infection Viral			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Upper Respiratory Tract Infection			
subjects affected / exposed	0 / 25 (0.00%)	2 / 19 (10.53%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Sinusitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 25 (0.00%)	1 / 19 (5.26%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	1 / 25 (4.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Iron Deficiency			
subjects affected / exposed	0 / 25 (0.00%)	0 / 19 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Vitamin B12 Deficiency subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 19 (0.00%) 0	0 / 7 (0.00%) 0
--	---------------------	---------------------	--------------------

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 July 2021	Amendment 5: The purpose for this amendment was a change in study treatment regimens, based on the availability of preliminary 48-week treatment data from the Phase 2b study REEF-1 (73763989HPB2001), and new data presented during the European Association for the Study of the Liver (EASL) conference of 2021 showing that HBsAg declines with siRNA treatment can be increased when combined with PegIFN.
30 September 2021	Amendment 6: The purpose for this amendment was to remove JNJ-6379 as study intervention, to add a new nucleos(t)ide analog (NA) re-treatment criterion for subjects who discontinued NA treatment during follow-up, and to include more frequent monitoring for subjects who discontinued NA treatment during follow-up.
25 November 2021	Amendment 7: The purpose of amendment was to update the criteria for post-treatment monitoring and for nucleos(t)ide analog (NA) re-treatment for participants who discontinued NA treatment during follow-up.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported